Medherant secures further funding for development of testosterone patch for post-menopausal women
3 April 2023. Medherant (Coventry, UK) announces that it has raised £2.9m of new funding from investors in a financing round led by Mercia Asset Management. Medherant will principally use the funding to progress development of a testosterone tr...
Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology
Unique transdermal delivery technology and medicines for rare diseases combine to deliver significant quality-of-life benefits for patients Cambridge & Coventry, UK – 5 May 2020 – Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (M...
Medherant positions itself for the next stage of its development with the appointment of a new CEO
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as...
Mercia invests £2.0 million in transdermal drug delivery specialist, Medherant
Coventry, UK, 21st May 2019 / Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch® technology, has today announced a new £2 million i...
Medherant announces positive Phase I results for its first transdermal drug delivery patch
Coventry, UK, 5th November 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI Patch®. The ...
Innovate UK Awards Medherant a Medicines Manufacturing Grant
New funding to support manufacture of transdermal patches for clinical trials Coventry, UK, 3rd October 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medicines M...
Medherant completes £3.8 million funding round
Coventry, UK, 11th December 2017 / Medherant, a leader in next-generation transdermal drug delivery, has raised £3.8 million in its latest funding round. The fundraising was led by majority shareholder Mercia Technologies PLC, with the balance ...
Medherant wins Excellence in Science & Technology Award
Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwicks...
Medherant signs agreement with leading Japanese transdermal patch company for evaluation of its TEPI Patch® drug delivery system
Coventry, UK, 27th September 2017 / Medherant, a leader in next-generation transdermal drug delivery, has signed an agreement with a Japanese transdermal patch company (“the company”), one of the world’s largest patch developers and manufa...
Medherant expands management team with appointment of Sally Waterman, COO and Angus Hone, CFO
Coventry, UK, 26th June 2017 / Medherant Ltd, a University of Warwick spin-out company developing a next-generation transdermal drug delivery patch technology, is pleased to announce the appointment of two new senior executives, Sally Waterman and An...